Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Prepaid Assets (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Prepaid Assets for 11 consecutive years, with $1.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Prepaid Assets changed N/A to $1.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.3 million, a N/A change, with the full-year FY2023 number at $2.0 million, down 29.75% from a year prior.
  • Prepaid Assets was $1.3 million for Q3 2025 at Crescent Biopharma, down from $1.6 million in the prior quarter.
  • In the past five years, Prepaid Assets ranged from a high of $2.8 million in Q4 2022 to a low of $273396.0 in Q4 2021.
  • A 5-year average of $1.3 million and a median of $1.4 million in 2024 define the central range for Prepaid Assets.
  • Peak YoY movement for Prepaid Assets: soared 940.28% in 2022, then tumbled 84.93% in 2025.
  • Crescent Biopharma's Prepaid Assets stood at $273396.0 in 2021, then skyrocketed by 940.28% to $2.8 million in 2022, then decreased by 29.75% to $2.0 million in 2023, then decreased by 26.35% to $1.5 million in 2024, then fell by 11.79% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for CBIO's Prepaid Assets are $1.3 million (Q3 2025), $1.6 million (Q2 2025), and $299232.0 (Q1 2025).